Leveraging Multivariate Analysis Tools to Qualify Scaled-Down Models

Process Validationin Manufacturing of Biopharmaceuticals, Third edition

Volumn , Issue , 2012, Pages 411-440

  Pieracci, John ^a   Yusuf Makagiansar, Helena ^b  

^a BIOGEN   (United States)

^b La Jolla Biologics Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893737333     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b12013-19     Document Type: Chapter

References (21)

1. CMC Biotech Working Group. 2009. “A-Mab: A Case Study in Bioprocess Development, Version 2.1.” http://www.casss.org/associations/9165/files/A-Mab_Case_Study_Version_2-1.pdf.
2. De Alwis, D., R. Dutton, et al. 2007. “Statistical Model in Media Optimization for Batch and Fed-Batch Animal Cell Culture.” Bioprocess and Biosystems Engineering 30: 7.
3. European Medicines Agency (EMEA). 2008. “Guideline on Virus Safety Evaluation of Biotechnological Investigational Medicinal Products, " http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003795.pdf.
4. Ganguly, J., and J. Thommes. 2010. Systems and Methods for Evaluating Chromatography Column Performance. United States Patent Application 20100127860, Application Number: 12/541014, Application Date: 05/27/2010, Filing Date: 08/13/2009.
5. Godavarti, R., J. Petrone, et al. 2005. “Scale-Down Models for Purification Processes: Approaches and Applications.” In Process Validation in Manufacturing of Biopharmaceuticals: Guidelines, Current Practices, and Industrial Case Studies. Edited by A. Rathore and G. Sofer. New York: Taylor and Francis, 69-142.
6. Heath, C., and R. Kiss. 2007. “Cell Culture Process Development: Advances in Process Engineering.” Biotechnology Progress 23(1): 6.
7. Kirdar, A., J. Conner, et al. 2007. “Application of Multivariate Analysis toward Biotech Processes: Case Study of a Cell-Culture Unit Operation.” Biotechnology Progress 23(1): 10.
8. Kirdar, A., K. Green, et al. 2008. “Application of Multivariate Data Analysis for Identification and Successful Resolution of a Root Cause for a Bioprocessing Application.” Biotechnology Progress 24(3): 7.
9. Kresta, J., J. MacGregor, et al. 1991. “Multivariate Statistical Monitoring of Process Operating Performance.” Canadian Journal of Chemical Engineering 69: 13.
10. Larson, T., J. Davis, et al. 2003. “Use of Process Data to Assess Chromatographic Performance in Production-Scale Protein Purification Columns.” Biotechnology Progress 19: 485-492.
11. Marks, D. 2003. “Equipment Design Considerations for Large-Scale Cell Culture.” Cytotechnology 42: 3.
12. Moscariello, J., G. Purdom, et al. 2001. “Characterizing the Performance of Industrial-Scale Columns.” Journal of Chromatography A 908: 131-141.
13. Nienow, A. 2006. “Reactor Engineering in Large-Scale Animal Cell Culture.” Cytotechnology 50: 35.
14. Parenteral Drug Association (PDA). 2008. “Validation of Column-Based Chromatography Processes for the Purification of Proteins.” PDA Journal of Pharmaceutical Science and Technology 62(S-3).
15. Pieracci, J., L. Perry, et al. 2010. “Using Partition Designs to Enhance Purification Process Understanding.” Biotechnology and Bioengineering 107(5): 814-824.
16. Q5A(R1) (1999). “Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin.” US Department of Health and Human Service, Food and Drug Administration (FDA).
17. Q8(R2), I. (2009). “Harmonized Tripartite Guideline on Pharmaceutical Development.” Guidance for Industry: Q8 Pharmaceutical Development, US Department of Health and Human Service, Food and Drug Administration (FDA). May, 2006. Q8 Annex Pharmaceutical Development, Step 3, November, 2007.
18. Seely, J. 2005. Process Characterization. In Process Validation in Manufacturing of Biopharmaceuticals: Guidelines, Current Practices, and Industrial Case Studies. Edited by A. Rathore and G. Sofer. New York: Taylor and Francis, 31-68.
19. US Food and Drug Administration (FDA). 1997. “Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use, " http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/OtherRecommendationsforManufacturers/UCM153182.pdf.
20. Wold, S., P. Geladi, et al. 1987. “Multiway Principal Components and PLS-analysis.” Journal of Chemometrics 1: 41-56.
21. Wolf, G., J. Almeida, et al. 2007. “An Improved Method for Two-Dimensional Fluorescence Monitoring of Complex Bioreactors.” Journal of Biotechnology 128: 12.